New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
10:11 EDTATML, CLF, HAL, HP, GILD, EFX, XLNX, TFM, PWER, PNM, O, MGM, LUFK, GNC, FET, CY, CRK, CRL, RVBDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Atmel (ATML) upgraded to Buy from Hold at Needham... Best Buy (BBY) upgraded to Overweight from Equal Weight at Barclays... Charles River Labs (CRL) upgraded to Buy from Hold at Jefferies... Comstock Resources (CRK) upgraded to Outperform from Market Perform at BMO Capital... Cypress Semiconductor (CY) upgraded to Buy from Hold at Needham... Forum Energy (FET) upgraded to Outperform from Market Perform at FBR Capital... GNC Holdings (GNC) upgraded to Buy from Neutral at Goldman... Lufkin (LUFK) upgraded to Outperform from Market Perform at Wells Fargo... MGM Resorts (MGM) upgraded to Outperform from Sector Perform at RBC Capital... Realty Income (O) upgraded to Buy from Neutral at BofA/Merrill... PNM Resources (PNM) upgraded to Buy from Hold at Jefferies... Power-One (PWER) upgraded to Strong Buy from Outperform at Raymond James... The Fresh Market (TFM) upgraded to Buy from Neutral at Goldman... Xilinx (XLNX) upgraded to Buy from Neutral at BofA/Merrill... Equifax (EFX) upgraded to Overweight from Equal Weight at Evercore... Best Buy (BBY) upgraded to Buy from Hold at Stifel Nicolaus... Gilead (GILD) upgraded to Outperform from Neutral at Credit Suisse... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Halliburton (HAL) upgraded to Overweight from Equal Weight at Stephens... Cliffs Natural (CLF) upgraded to Overweight from Neutral at JPMorgan... Riverbed (RVBD) upgraded to Strong Buy from Buy at Needham.
News For ATML;CRL;CRK;CY;FET;GNC;LUFK;MGM;O;PNM;PWER;TFM;XLNX;EFX;GILD;HP;HAL;CLF;RVBD From The Last 14 Days
Check below for free stories on ATML;CRL;CRK;CY;FET;GNC;LUFK;MGM;O;PNM;PWER;TFM;XLNX;EFX;GILD;HP;HAL;CLF;RVBD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 20, 2014
08:53 EDTCRLCharles River Labs has reached attractive entry point, says Sterne Agee
Sterne Agee continues to believe that Charles River should generate high incremental margins and disproportionate growth in earnings relative to its sales growth. The firm keeps a $71 price target and Buy rating on the shares.
08:51 EDTGNCGNC purchase of shares by chairman a vote of confidence, says Sterne Agee
Subscribe for More Information
August 19, 2014
16:00 EDTGILDOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
August 18, 2014
16:02 EDTRVBDRiverbed names Paul Mountford as Chief Sales Officer
Riverbed Technology announced that Paul Mountford has joined the company as senior vice president and Chief Sales Officer. He was most recently CEO of Sentillian, a New York-based web intelligence startup.
16:00 EDTGILDOptions Update; August 18, 2014
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN DG TSLA GILD FB ABX WFC C
August 15, 2014
16:00 EDTGILDOptions Update; August 15, 2014
iPath S&P 500 VIX Short-Term Futures up 1c to 28.88. Option volume leaders: AAPL GILD NFLX PBR TWTR TSLA MNKD AMZN C according to Track Data.
10:01 EDTGILDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:36 EDTCLFCliffs pays $11M to Halverson in connection with employment termination
Subscribe for More Information
06:18 EDTGILDGilead initiated with an Outperform at FBR Capital
Subscribe for More Information
06:12 EDTGILDGilead announced favorable ruling in arbitration against Roche
Gilead (GILD) announced that an arbitration panel determined that Roche (RHHBY) failed to establish any of their claims and ruled in favor of Gilead. As a result, Roche is not entitled to any damages or other relief. In March 2013, Roche initiated an arbitration against Gilead and Pharmasset, predecessor to Gilead Pharmasset, regarding a 2004 collaboration agreement between Roche and Pharmasset. In the arbitration demand, Roche asserted that it had an exclusive license to sofosbuvir pursuant to the collaboration agreement because sofosbuvir, a prodrug of a uridine monophosphate analog, is allegedly a prodrug of PSI-6130, a cytidine analog. Roche further claimed that, because it had exclusive rights to sofosbuvir, it also had an exclusive license to a patent covering sofosbuvir, and that we infringed that patent by selling and offering for sale products containing sofosbuvir.
August 14, 2014
17:20 EDTGNCTrian Fund gives quarterly update on stakes
Subscribe for More Information
16:01 EDTGILDOptions Update; August 14, 2014
Subscribe for More Information
10:05 EDTHPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:41 EDTHPHelmerich & Payne upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse upgraded Helmerich & Payne to Outperform and raised its price target to $96 from $90 based on valuation and reduced expectations.
August 13, 2014
16:15 EDTGNCGNC Holdings increases share repurchase authorization to $500M
Subscribe for More Information
13:57 EDTMGMNJ reports Atlantic City July gaming win down 7.7% to $274.3M
Subscribe for More Information
12:22 EDTCLFIron ore prices at lowest level in months, Business Spectator says
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use